PET/CT in non-small cell lung cancer staging-promises and problems

Clinical Radiology

Volumn 62, Issue 2, 2007, Pages 97-108

  Devaraj, A ^a   Cook, G J R ^b   Hansell, D M ^c  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18;

CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; IMAGE PROCESSING; LUNG NON SMALL CELL CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW;

CARCINOMA, NON-SMALL-CELL LUNG; CONTRAST MEDIA; COST-BENEFIT ANALYSIS; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FLUORODEOXYGLUCOSE F18; HEALTH CARE COSTS; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33845888825     PISSN: 00099260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crad.2006.09.015     Document Type: Review

References (81)

1. Janssen-Heijnen M.L.G., and Coebergh J.W. Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe. Lung Cancer 31 (2001) 123-137
2. Kernstine K.H., Grannis F.W., and Rotter A.J. Is there a role for PET in the evaluation of subcentimeter pulmonary nodules?. Thorac Cardiovasc Surg 17 (2005) 110-114
3. Townsend D.W., Carney J.P., Yap J.T., et al. PET/CT today tomorrow. J Nucl Med 45S (2004) 4S-14S
4. Townsend D.W. A combined PET/CT scanner: the choices. (Letter). J Nucl Med 42 (2001) 533-534
5. Department of Health. A framework for the development of Positron Emission Tomography (PET) services in England. 2005. Available at http://www.doh.gov.uk (accessed 17th July 2006)
6. Delbeke D., Coleman R.E., Guiberteau M.J., et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 47 (2006) 885-895
7. Von Schulthess G.K., Steinert H.C., and Hany T.F. Integrated PET/CT: current applications and future directions. Radiology 238 (2006) 405-422
8. Yau Y.Y., Chan W.S., Tam Y.M., et al. Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error?. J Nucl Med 46 (2005) 283-291
9. Berthelsen A.K., Holm S., Loft A., et al. PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients. Eur J Nucl Med Mol Imaging 32 (2005) 1167-1175
10. Mawlawi O., Erasmus J.J., Munden R.F., et al. Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation. AJR Am J Roentgenol 186 (2006) 308-319
11. Armstrong P., and Vincent J.M. Staging non-small cell lung cancer. Clin Radiol 48 (1993) 1-10
12. Pisters K.M. Adjuvant chemotherapy for non-small-cell lung cancer-the smoke clears. N Engl J Med 352 (2005) 2640-2642
13. Quint L.E., and Francis I.R. Radiologic staging of lung cancer. J Thoracic Imaging 14 (1999) 235-246
14. Mori K., Takashi T., Machida S., et al. Helical computed tomography diagnosis of pleural dissemination in lung cancer: comparison of thick-section and thin-section helical computed tomography. J Thoracic Imaging 13 (1998) 211-218
15. Higashino T., Ohno Y., Takenaka D., et al. Thin-section multiplanar reformats from multidetector-row CT data: utility for assessment of regional tumor extent in non-small cell lung cancer. Eur J Radiol 56 (2005) 48-55
16. Chooi W.K., Mattews S., Bull M., et al. Multislice computed tomography in staging lung cancer: The role of multiplanar image reconstruction. J Comput Assist Tomogr 29 (2005) 357-360
17. Munden R.F., Swisher S.S., Stevens C.W., et al. Imaging of the patient with non-small cell lung cancer. Radiology 237 (2005) 803-818
18. Brim O., Kappetein A.P., Stijnen T., et al. Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thorac Surg 79 (2005) 375-381
19. Toloza E.M., Harpole L., McCrory M.P., et al. Noninvasive staging of non-small cell lung cancer: A review of the current evidence. Chest 123 (2003) 137S-146S
20. Dales R.E., Stark R.M., and Raman S. Computed tomography to stage lung cancer: approaching a controversy using meta-analysis. Am Rev Respir Dis 141 (1990) 1096-1101
21. Yokoi K., Kamiya N., Matsuguma J., et al. Detection of brain metastases in potentially operable non-small cell lung cancer. A comparison of CT and MRI. Chest 115 (1999) 714-719
22. Kormas P., Bradshaw J.R., and Jeyasingham K. Preoperative computed tomography of the brain in non-small cell bronchogenic carcinoma. Thorax 47 (1992) 106-108
23. Win T., Laroche C.M., Groves A.M., et al. The value of performing head CT in screening for cerebral metastases in patients with potentially resectable non-small cell lung cancer: experience from a UK cardiothoracic centre. Clin Radiol 59 (2004) 935-938
24. Pope R.J., and Hansell D.M. Extra-thoracic staging of lung cancer. Eur J Radiol 45 (2003) 31-38
25. Pagani J.J. Normal adrenal glands in small cell lung carcinoma: CT-guided biopsy. Am J Roentgenol 140 (1983) 949-951
26. Lavrenov K., Partridge M., Cook G., et al. Positron emission tomography for target volume definition in the treatment of non-small cell lung cancer. Radiother Oncol 77 (2005) 1-4
27. Gupta N.C., Rogers J.S., Graeber G.M., et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion. Chest 122 (2002) 1918-1924
28. Aquino S.L., Webb W.R., and Gushiken B.J. Pleural exudates and transudates: diagnosis with contrast enhanced CT. Radiology 192 (1994) 803-808
29. Gould M.K., Kuschner W.G., Rydzak C.E., et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with Non-small cell lung cancer. Ann Intern Med 139 (2003) 879-891
30. Dwamena B.A., Sonnad S.S., Angobaldo J.O., et al. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s; meta-analytic comparison of PET and CT. Radiology 213 (1999) 530-536
31. Pieterman R.M., van Putten J.W.G., Meuzelaar J.J., et al. Preoperative staging of non-small cell lung cancer with positron-emission tomography. N Eng J Med 343 (2000) 254-261
32. Schrevens L., Lornet N., Dooms C., et al. The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer. Oncologist 9 (2004) 633-643
33. De Langen A.J., Raijmakers P., Riphagen I., et al. The size of mediastinal lymph nodes and its relation with metastatic involvement: a meta-analysis. Eur J Cardiothorac Surg 29 (2006) 26-29
34. Weder W., Schmid R.A., Bruchhaus H., et al. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 66 (1998) 886-892
35. Van Tinteren H., Hoekstra O.S., Smit E.F., et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 359 (2002) 1388-1392
36. Erasmus J.J., Patz E.F., McAdams H.P., et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 168 (1997) 1357-1360
37. Kumar R., Xiu Y., Yu J.Q., et al. 18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. J Nucl Med 45 (2004) 2058-2062
38. Jana S., Zhang T., Milstein D.M., et al. FDG-PET and CT characterization of adrenal lesions in cancer patients. Eur J Nucl Med Mol Imaging 33 (2006) 29-35
39. Marorn E.M., McAdams H.P., Erasmus J.J., et al. Staging non-small cell lung cancer with whole-body PET. Radiology 212 (1999) 803-809
40. Wiering B., Krabbe P.F., Jager G.J., et al. The impact of fluoro-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 104 (2005) 2658-2670
41. Bury T., Barreto A., Daenen F., et al. Fluorine-18-deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 25 (1998) 1244-1247
42. Brink I., Schumacher T., Mix M., et al. Impact of 18F-FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 31 (2004) 1614-1620
43. Higashi K., Yoshimichi U., Arisaka Y., et al. F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 43 (2002) 39-45
44. Eschmann S.M., Friedel G., Paulsen F., et al. Is standardised F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer?. Eur J Nucl Med Mol Imaging 33 (2006) 263-269
45. Prevost S., Boucher L., Larivee P., et al. Bone marrow hypermetabolism on 18F-FDG PET as a survival prognostic factor in non-small cell lung cancer. J Nucl Med 47 (2006) 559-565
46. Halpern B.S., Schiepers C., Weber W.A., et al. Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest 128 (2005) 2289-2297
47. Shim S.S., Kyung S.L., Byung-Tae K., et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology 236 (2005) 1011-1019
48. Lardinois D., Weder W., Hany T.F., et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348 (2003) 2500-2507
49. Antoch G., Stattaus J., Nemat A.T., et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 229 (2003) 526-533
50. Gilman M.D., and Aquino S.L. State-of-the-art FDG-PET imaging of lung cancer. Semin Roentgenol 40 (2005) 143-153
51. Schuster D.P. The evaluation of lung function with PET. Semin Nucl Med 28 (1998) 341
52. Bakheet S.M., Saleem M., Powe J., et al. F-18 fluorodeoxyglucose chest uptake in lung inflammation and infection. Clin Nucl Med 25 (2000) 273-278
53. Lohr R.H., Boland B.J., Douglas W.W., et al. Organising pneumonia. Features and prognosis of cryptogenic, secondary and focal variants. Arch Intern Med 74 (1997) 201-211
54. Asad S., Aquino S.L., Piyavisetpat N., et al. False positive FDG positron emission tomography uptake in non-malignant chest abnormalities. AJR Am J Roentgenol 182 (2004) 983-989
55. Grubstein A., Shitrit D., Sapir E.E., et al. Pulmonary amyloidosis: detection with PET-CT. Clinical Nuclear Medicine 30 (2005) 420-421
56. Kamel E.M., McKee T.A., Calcagni M.L., et al. Occult lung infarction may induce false interpretation of 18F-FDG PET in primary staging of pulmonary malignancies. Eur J Nucl Med Mol Imaging 32 (2005) 641-646
57. Konishi J., Yamazaki K., Tsukamoto E., et al. Mediastinal lymph node staging by FDG-PET in patients with non-small cell lung cancer: analysis of false-positive FDG-PET findings. Respiration 70 (2003) 500-506
58. Roberts P., Follette D.M., von Haag D., et al. Factors associated with false-positive staging of lung cancer by positron emission tomography. Ann Thorac Surg 70 (2000) 1154-1160
59. Hara M., Shiraki N., Itoh M., et al. A Problem in diagnosing N3 disease using FDG-PET in patients with lung cancer - High false positive rate with visual assessment. An Nucl Med 18 (2004) 483-488
60. Bunyaviroch T., and Cole R.E. PET evaluation of Lung Cancer. J Nucl Med 47 (2006) 451-469
61. Weiss N., and Solomon S.B. Talc pleurodesis mimics pleura metastases: differentiation with positron emission tomography/computed tomography. Clin Nucl Med 28 (2003) 811-814
62. Kwek B.H., Aquino S.L., and Fishcman A.J. Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis. Chest 125 (2004) 2356-2360
63. Schaffler G.J., Wolf G., Schoellnast H., et al. Non-small cell lung cancer: evaluation of pleural abnormalities on CT scans with 18F FDG PET. Radiology 231 (2004) 858-865
64. Lardinois D., Weder W., Roudad M., et al. Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer. J Clin Oncol 23 (2005) 6846-6853
65. Truong M.T., Erasmus J.J., Macapinlac H.A., et al. Integrated positron emission tomography/computed tomography in patients with non-small cell lung cancer: normal variants and pitfalls. J Comput Assist Tomogr 29 (2005) 205-209
66. Truong M.Y., Erasmus J.J., Munden R.F., et al. Focal FDG uptake in mediastinal brown fat mimicking malignancy: a potential pitfall resolved on PET/CT. AJR Am J Roentgenol 183 (2004) 1127-1132
67. Reinhardt M.J., Wiethoelter N., Matthies A., et al. PET recognition of pulmonary metastases on PET/CT imaging: impact of attenuation-corrected and non-attenuation-corrected PET images. Eur J Nucl Med Mol Imaging 33 (2006) 134-139
68. Takamochi K., Yoshida J., Murakami K., et al. Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients. Lung Cancer 47 (2005) 235-242
69. Poncelat A.J., Lonneux M., Coche E., et al. PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma. Eur J Cardiothorac Surg 20 (2001) 468-475
70. Kim B.T., Kim Y., Lee K.S., et al. Localised form of bronchioalveolar cell carcinoma: FDG PET findings. Am J Roentgenol 170 (1998) 935-939
71. Higashi K., Ueda Y., Seki H., et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar cell lung carcinoma. J Nucl Med 39 (1998) 1016-1020
72. Fuster D., Chiang S., Johnson G., et al. Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma?. J Nucl Med 45 (2004) 1323-1327
73. Cohade C., Osman M., Marshall L.T., et al. PET-CT: accuracy of PET and CT spatial registration of lung lesions. Eur J Nucl Med Mol Imaging 30 (2003) 721-726
74. Goerres G.W., Burger C., Kamel E., et al. Respiration-induced attenuation artifact at PET/CT: technical considerations. Radiology 226 (2003) 906-910
75. Juergens K.U., Weckesser M., Stegger L., et al. Tumor staging using whole-body high-resolution 16-channel PET-CT: does additional low-dose chest CT in inspiration improve the detection of solitary pulmonary nodules?. Eur Radiol 16 (2006) 1131-1137
76. Viney R.C., Boyer M.J., King M.T., et al. Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. J Clin Oncol 22 (2004) 2357-2362
77. Verboom P., van Tinteren H., Hoekstra O.S., et al. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study. Eur J Nucl Med Mol Imaging 30 (2003) 1444-1449
78. Rusch V.W. Mediastinoscopy: an endangered species?. J Clin Oncol 23 (2005) 8283-8285
79. Alzahouri K., Lejeune C., Woronoff-Lemski M.C., et al. Cost-effectiveness analysis of strategies introducing FDG-PET into the mediastinal staging of non-small-cell lung cancer from the French healthcare system perspective. Clin Radiol 60 (2005) 479-492
80. Yap K.K., Yap K.S., Byrne A.J., et al. Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer. Eur J Nucl Med Mol Imaging 32 (2005) 1033-1040
81. National Institute for Clinical Excellence. The diagnosis and treatment of lung cancer. 2005. Available at http://www.nice.org.uk (accessed on 17th July 2006)